tirzepatide fda approval for weight loss Grants a New Indication Obesity Management Diabetes Drug - Tirzepatide Gets

Clinical Studies 14.1 Weight Reduction and Long-Term Maintenance Studies in Adults with Obesity or Overweight Weight Reduction in Adults with Obesity or Overweight, with or without Type 2 Diabetes Mellitus (Study 1 and Study 2) Overview of Study 1 and Study 2 The efficacy of ZEPBOUND for weight reduction in conjunction with a reduced-calorie diet and increased physical activity was studied in two randomized, double-blind, placebo-controlled fixed-dosage trials (Study 1 and Study 2) in adults aged 18 years and older

Keywords: dual agonists, incretin based therapy, tirzepatide, type 2 diabetes, obesity, glucagon-like peptide-1 receptor agonists 1

Think of these as switches that control your hunger and how your body handles sugar

This allows the body to adjust to the GLP-1 and GIP receptor activation before increasing the dose